4.2 Oral & Mucosal Toxicities: Stomatitis, Mucositis, Dysgeusia, & Xerostomia
Key Takeaways
- Oral mucositis develops through a 5-phase pathological cascade (Initiation, Primary Damage Response, Signal Amplification, Ulceration, and Healing); WHO Grade 3 is defined by confluent painful mucosal ulcers requiring a liquid diet, while Grade 4 makes oral feeding impossible.
- MASCC/ISOO clinical practice guidelines strongly endorse 30-minute ice chip oral cryotherapy during bolus 5-Fluorouracil (5-FU) or high-dose Melphalan infusions to induce local vasoconstriction and attenuate mucosal drug toxicity.
- Dysgeusia presenting as a metallic taste (common with cisplatin, carboplatin, and cyclophosphamide) is managed using non-metallic utensils, marinating proteins in acidic or sweet glazes, and supplemental Zinc Sulfate (220 mg daily providing 45-50 mg elemental zinc) for verified/suspected deficiency.
- Radiation to head and neck structures exceeding 20-30 Gy causes permanent salivary gland acinar cell destruction and severe xerostomia, managed with sialogogues (pilocarpine, cevimeline), artificial saliva, and moistening agents (gravies, sauces, fats).
4.2 Oral & Mucosal Toxicities: Stomatitis, Mucositis, Dysgeusia, & Xerostomia
Oral and mucosal toxicities are frequent, severe complications of antineoplastic therapy, occurring in up to 40% of patients receiving standard chemotherapy, 80% of patients undergoing hematopoietic stem cell transplantation (HSCT), and nearly 100% of patients receiving definitive radiation therapy for head and neck squamous cell carcinoma (HNSCC). These toxicities cause severe odynophagia, profound reduction in oral intake, weight loss, secondary bacterial and fungal infections, prolonged hospitalizations, and frequent interruptions in cancer treatment.
Pathophysiology of Oral Mucositis: The 5-Phase Model
Oral mucositis is not merely a superficial epithelial injury, but a complex biological process involving all cellular layers of the mucosa. Sonis's 5-Phase Model details this cascade:
- Initiation Phase: Chemotherapy or ionizing radiation directly damages epithelial cell DNA and generates reactive oxygen species (ROS), triggering non-DNA damage and cellular stress responses.
- Primary Damage Response Phase: ROS activate transcription factors, notably Nuclear Factor-kappa B (NF-$\kappa$B), upregulating pro-inflammatory cytokines (TNF-$\alpha$, IL-1$\beta$, IL-6) and damaging submucosal vascular endothelial cells.
- Signal Amplification Phase: Pro-inflammatory cytokines execute positive feedback loops, causing further tissue damage, apoptosis of basal epithelial stem cells, and mucosal thinning.
- Ulceration & Clinical Phase: The mucosal barrier breaks down, producing deep, confluent, painful ulcerations covered by a pseudomembranous exudate. Local bacterial colonization by Gram-negative and Gram-positive oral flora occurs, further driving inflammatory cytokine release and elevating systemic bacteremia risk in neutropenic patients.
- Healing Phase: Epithelial proliferation and differentiation restore mucosal integrity, typically occurring 2–3 weeks post-chemotherapy or following radiation completion.
Diagnostic & Functional Grading Scales
Accurate grading of oral mucositis guides clinical decision-making regarding oral analgesia, dietary consistency modifications, and the initiation of tube feeding or total parenteral nutrition (TPN).
| Grade | WHO Oral Mucositis Scale | NCI CTCAE v5.0 Clinical Criteria | Functional & Nutritional Impact |
|---|---|---|---|
| Grade 0 | None | No symptoms / normal mucosa | Normal oral intake; regular diet. |
| Grade 1 | Soreness / mild erythema | Asymptomatic or mild symptoms; erythema | Able to eat a regular solid diet; mild mucosal discomfort. |
| Grade 2 | Erythema, solitary painful ulcers; able to swallow solid foods | Moderate pain; painful erythema or ulcers; does not interfere with oral intake | Patient requires a soft, non-irritating diet; solid food swallowing intact. |
| Grade 3 | Confluent, painful ulcers; requires liquid diet | Severe pain; interfering with oral intake | Patient cannot swallow solid food; restricted to liquid diet/ONS. |
| Grade 4 | Deep ulcerations, hemorrhage, necrosis; oral alimentary impossible | Life-threatening consequences; urgent intervention indicated | Oral alimentation is completely impossible; EN or TPN required. |
| Grade 5 | Death | Death | N/A |
MASCC/ISOO Guidelines & Evidence-Based Interventions
The Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) provide gold-standard clinical recommendations:
1. Oral Cryotherapy Protocol
- Mechanism: Cold-induced local vasoconstriction significantly reduces blood flow to the oral mucosa during peak plasma drug concentrations, minimizing chemotherapeutic drug delivery to vulnerable stem cells.
- Protocol: Swish ice chips or ice water in the mouth for 30 minutes starting 5 minutes prior to bolus 5-Fluorouracil (5-FU) administration or high-dose Melphalan conditioning prior to HSCT.
2. Basic Oral Hygiene Protocols
- Utilize ultra-soft toothbrushing and gentle non-waxed flossing daily.
- Perform frequent oral rinses (4–6 times daily) with a non-alcoholic, isotonic salt and soda wash (1/2 tsp salt + 1/2 tsp sodium bicarbonate in 1 quart warm water). Avoid commercial alcohol-containing mouthwashes.
- Avoid chlorhexidine rinses during active head and neck radiation (ineffective for preventing radiation mucositis and causes severe burning).
3. Compounded Topical Formulations ("Magic Mouthwash")
Compounded palliative mouthwashes typically combine equal parts of:
- Topical Anesthetic: Viscous Lidocaine (2%) for mucosal analgesia.
- Antihistamine/Anti-inflammatory: Diphenhydramine liquid.
- Coating Agent/Antacid: Aluminum & Magnesium Hydroxide or Bismuth Subsalicylate.
- Antifungal: Nystatin oral suspension (if candidiasis is present).
- Clinical Warning: Instruct patients to swish and spit 5 minutes before meals. Caution against swallowing viscous lidocaine due to loss of the protective gag reflex and potential aspiration.
4. Systemic & Targeted Therapies
- Palifermin (Recombinant Human Keratinocyte Growth Factor-1): Administered IV for 3 consecutive days before and after myeloablative conditioning for HSCT to stimulate epithelial cell proliferation.
- Oral Glutamine Rinses: Oral glutamine (swish and swallow, 30 g/day in 3 divided doses) provides fuel for enterocytes and attenuates mucosal injury in select chemotherapy and radiation cohorts.
Dysgeusia & Taste Distortions
Dysgeusia (altered taste perception), hypogeusia (reduced acuity), and ageusia (loss of taste) result from chemotherapy-induced damage to taste receptor cells (which have a rapid 10–14 day turnover) or radiation to the tongue's circumvallate and foliate papillae.
- Metallic Taste Pathophysiology: Classically induced by platinum chemotherapy (Cisplatin, Carboplatin) and alkylating agents (Cyclophosphamide).
- MNT Strategies for Metallic & Altered Taste:
- Switch to plastic, bamboo, or wooden utensils and glass cookware to eliminate metallic contact.
- Marinate proteins (chicken, fish, tofu) in acidic juices (lemon, lime, orange) or sweet glazes (teriyaki, maple syrup, honey mustard).
- Add tart, citrus, mint, or bold seasonings (rosemary, oregano) to mask off-tastes (provided mucositis is absent).
- Serve protein sources cold or room-temperature (e.g., chicken salad, cottage cheese, deviled eggs).
- Zinc Supplementation Protocol: Zinc is an essential cofactor for carbonic anhydrase VI (gustin), a major salivary protein required for taste bud development. Supplemental Zinc Sulfate 220 mg daily (providing 45 to 50 mg elemental zinc) for 60 to 90 days is indicated for dysgeusia associated with verified or suspected zinc deficiency, while monitoring serum copper levels.
Xerostomia & Salivary Gland Dysfunction
Radiation therapy to head and neck structures exceeding cumulative doses of 20 to 30 Gray (Gy) causes irreversible microvascular damage and acinar cell necrosis in the parotid and submandibular salivary glands. Doses $>40 ext{–}50 ext{ Gy}$ produce permanent, complete salivary gland destruction.
- Clinical Manifestations: Thick ropey saliva, loss of bolus lubrication, rampant dental caries, oral candidiasis, and severe mechanical dysphagia.
- MNT Strategies for Xerostomia:
- Add generous amounts of gravies, sauces, broths, melted butter, mayonnaise, sour cream, or salad dressings to all solid foods.
- Maintain continuous oral hydration by taking frequent small sips of water throughout the day.
- Utilize commercial artificial saliva substitutes (carboxymethylcellulose or mucin-based sprays and gels).
- Suck on sugar-free hard candies or chew sugar-free gum containing xylitol to stimulate residual functional salivary acini.
- Pharmacological Sialogogues: Muscarinic receptor agonists such as Pilocarpine (5 mg TID) or Cevimeline (30 mg TID) directly stimulate functional exocrine tissue to increase saliva output. Avoid caffeine, alcohol, and dry, crunchy foods.
Clinical Case & MNT Decision Algorithm
Patient Profile: A 62-year-old male undergoing concurrent Cisplatin and 66 Gy radiation for Stage IV oral cavity cancer presents at Week 4 with confluent oral ulcerations, severe odynophagia (pain score 9/10), thick secretions, and inability to swallow soft solids. Weight loss is 8% over 3 weeks.
MNT Assessment & Action Plan:
- Mucositis Grading: Confluent ulcerations restricting intake to liquids equals WHO Grade 3 / CTCAE Grade 3. Pain score 9/10 requires systemic opioid analgesia.
- Nutritional Support Decision: Oral intake is insufficient (<50% estimated energy requirements). Place a prophylactic prophylactic nasogastric (NG) tube or percutaneous endoscopic gastrostomy (PEG) tube to initiate enteral tube feeding with a isotonic polymeric or peptide formula.
- Topical Hygiene Plan: Initiate salt/soda washes q2h, magic mouthwash PRN before oral hygiene, and pilocarpine 5 mg TID for xerostomia.
A patient with head and neck cancer undergoing radiation therapy presents with confluent, painful oral ulcerations. The patient is unable to swallow soft solid foods and is restricted entirely to liquids. According to the WHO Oral Mucositis Scale, which grade applies?
What is the primary physiological mechanism and clinical protocol for oral cryotherapy during bolus 5-Fluorouracil (5-FU) chemotherapy administration?
A patient receiving cisplatin chemotherapy reports a severe, persistent metallic taste that causes meat aversion. Which MNT intervention and mineral protocol are most targeted for this symptom?
At what cumulative radiation dose to the major salivary glands does permanent acinar cell necrosis and irreversible xerostomia typically manifest?